Nexstim Secures New European Order for NBS System 5
Nexstim Plc (NXTMH:HEX) has proudly announced the receipt of an order for its groundbreaking NBS System 5. This achievement represents a key milestone as the company partners with a new customer in Europe through its extensive distributor network.
Understanding the NBS System 5 Technology
The Nexstim Navigated Brain Stimulation (NBS) System 5 is unique as it is the only navigated TMS (Transcranial Magnetic Stimulation) system that has received both FDA clearance and CE marking. This advanced technology plays a crucial role in pre-operative mapping of the brain's motor and speech areas, enabling neurosurgeons to conduct intricate surgical procedures with enhanced accuracy.
CEO Remarks on the Order
Mikko Karvinen, the CEO of Nexstim, shared his excitement regarding this new order, stating, "Our cutting-edge technology supports neurosurgeons in their surgical planning, ultimately helping to maintain the quality of life for patients. Growing our customer base is essential, as each new system broadens access to vital pre-operative mapping services. It's encouraging to see our growth bolstered by a strong distributor network."
Nexstim's Global Presence and Mission
Based in Finland, Nexstim is a globally-oriented company committed to developing innovative medical technologies. The organization strives to offer personalized and effective diagnostics and therapies for complex brain disorders. Their pioneering non-invasive brain stimulation technology enables precise targeting through advanced 3D navigation.
Diagnostic and Therapy Business Focus
Nexstim places a significant emphasis on its Diagnostics Business, which focuses on the commercialization of the NBS system. The NBS System 5 is essential for presurgical mapping, ensuring thorough evaluation of speech and motor cortices before surgical interventions. Additionally, Nexstim provides the NBS System 6, which is FDA cleared for treating major depressive disorder in the U.S. and CE marked in Europe for similar conditions and chronic neuropathic pain.
Future Developments and Strategic Growth
Nexstim is listed on the Nasdaq First North Growth Market Finland, highlighting its ongoing dedication to expanding access to effective medical technology worldwide. The recent order for the NBS System 5 is part of Nexstim's strategy to enhance its market presence and improve patient care through advanced technology.
Frequently Asked Questions
What is the NBS System 5?
The NBS System 5 is a navigated TMS system designed for pre-operative mapping of brain areas responsible for motor and speech functions.
Why is this order significant for Nexstim?
This order signifies Nexstim's expanding presence and ability to provide advanced medical technology in Europe, which enhances patient care options.
Who can benefit from the NBS System 5?
Neurosurgeons and patients undergoing brain surgeries can benefit from the precise mapping capabilities offered by the NBS System 5.
What are Nexstim's future plans?
Nexstim aims to continue expanding its customer base and enhance access to its innovative medical technologies across the globe.
How can interested parties get more information?
For more information, parties can visit Nexstim’s official website or contact their CEO, Mikko Karvinen.
